Laekna, Inc.

來凱醫藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2105)

VOLUNTARY ANNOUNCEMENT

SUBCUTANEOUS COHORT INITIATED IN PHASE I CLINICAL TRIAL OF LAE102 FOR THE TREATMENT OF OBESITY

This announcement is made by Laekna, Inc. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business update of the Group.

The board (the "**Board**") of directors of the Company (the "**Directors**") is pleased to announce that the Group has initiated subcutaneous dosing cohort in its phase I single ascending dose study (the "**SAD Study**"). The phase I clinical trial is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability and pharmacokinetics of LAE102 administered both intravenously and subcutaneously. The phase I clinical trial is progressing effectively. As of September 30, 2024, more than half of the planned cohorts in intravenous injection route of administration have been dosed. Early signs of target engagements and expected pharmacodynamic biomarker changes have been observed. The Group is on track to achieve primary completion of the SAD Study before the end of 2024.

The Group targets to bring this precision therapy to overweight and obesity patients who are in need of novel treatment options for achieving quality weight control.

About LAE102

LAE102 is an internally discovered monoclonal antibody selectively targeting ActRIIA, a receptor that plays an important role in muscle regeneration and lipid metabolism. In the pre-clinical models, LAE102 has shown to increase lean mass and decrease fat mass. In combination with GLP1R agonist, LAE102 can further reduce fat mass and significantly regain the lean mass loss induced by GLP1R agonist. This positions LAE102 as a promising drug candidate for achieving quality weight control.

RISK WARNING

LAE102 MAY NOT ULTIMATELY BE SUCCESSFULLY DEVELOPED AND COMMERCIALIZED. THE COMPANY'S SHAREHOLDERS AND POTENTIAL INVESTORS ARE REMINDED TO EXERCISE CAUTION WHEN DEALING IN THE SECURITIES OF THE COMPANY.

By Order of the Board
Laekna, Inc.
Dr. LU Chris Xiangyang
Chairman

Hong Kong, October 18, 2024

As at the date of this announcement, the Board comprises Dr. LU Chris Xiangyang, Ms. XIE Ling and Dr. GU Xiang-Ju Justin as executive Directors; Dr. WANG David Guowei and Mr. SUN Yuan as non-executive Directors; and Dr. YIN Xudong, Dr. LI Min and Mr. ZHOU Jian as independent non-executive Directors.